The changing landscape of therapeutic strategies for recurrent ovarian cancer

Future Oncology

Volumn 8, Issue 9, 2012, Pages 1135-1147

  Baumann, Klaus H ^a   Wagner, Uwe ^a   Du Bois, Andreas ^b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

Author keywords

intraoperative radiation; recurrent ovarian cancer; surgery; targeted therapy

Indexed keywords

AFLIBERCEPT; BELINOSTAT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; INIPARIB; IRINOTECAN; NINTEDANIB; OLAPARIB; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PLACEBO; SAGOPILONE; SORAFENIB; SUNITINIB; TOPOTECAN; TRABECTEDIN; TRASTUZUMAB; TREBANANIB; UNINDEXED DRUG; VANDETANIB; VINTAFOLIDE; ZOPTARELIN DOXORUBICIN;

BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS;

EID: 84867034899     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.112     Document Type: Review

References (84)

1. Piccart MJ, Bertelsen K, Stuart G et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int. J. Gynecol. Cancer 13, 144-148 (2003).
2. Rochon J, du Bois A. Clinical research in epithelial ovarian cancer and patients' outcome. Ann. Oncol. 22(Suppl. 7), vii16-vii19 (2011).
3. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 5, 26-35 (2000).
4. Friedlander M, Trimble E, Tinker A et al. Clinical trials in recurrent ovarian cancer. Int. J. Gynecol. Cancer 21, 771-775 (2011).
5. Gorringe KL, Ramakrishna M, Williams LH et al. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. Genes Chromosomes Cancer 48, 931-942 (2009).
6. Selvanayagam ZE, Cheung TH, Wei N et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet. Cytogenet. 154, 63-66 (2004).
7. Ferriss JS, Kim Y, Duska L et al. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS ONE 7(2), e30550 (2012).
8. Arienti C, Tesei A, Verdecchia GM et al. Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. J. Transl Med. 9, 94 (2011).
9. Markman M. Counterpoint: chemosensitivity assays for recurrent ovarian cancer. J. Natl Compr. Cancer Netw. 9, 121-124 (2011).
10. Schink JC, Copeland LJ. Point: chemosensitivity assays have a role in the management of recurrent ovarian cancer. J. Natl Compr. Cancer Netw. 9, 115-120 (2011).
11. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst. 95, 1320-1329 (2003).
12. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473-2483 (2011).
13. Perren TJ, Swart AM, Pfisterer J et al. A Phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484-2496 (2011).
14. Rustin GJ, van der Burg ME, Griffin CL et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/ EORTC 55955): a randomised trial. Lancet 376, 1155-1163 (2010).
15. Thrall MM, DeLoia JA, Gallion H et al. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol. Oncol. 105, 17-22 (2007).
16. Fulham MJ, Carter J, Baldey A et al. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol. Oncol. 112, 462-468 (2009).
17. Pfisterer J, Harter P, Canzler U et al. The role of surgery in recurrent ovarian cancer. Int. J. Gynecol. Cancer 15, 195-198 (2005).
18. du Bois A, Harter P. The role of surgery in advanced and recurrent ovarian cancer. Ann. Oncol. 17(Suppl. 10), x235-x240 (2006).
19. Harter P, Sehouli J, Reuss A et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int. J. Gynecol. Cancer 21, 289-295 (2011).
20. Harter P, Hahmann M, Lueck HJ et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann. Surg. Oncol. 16, 1324-1330 (2009).
21. Heitz F, du Bois A, Kurzeder C et al. Surgery for recurrent ovarian cancer. Womens Health (Lond. Engl.) 7(5), 529-535 (2011).
22. Galaal K, Naik R, Bristow RE et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst. Rev. 16, CD007822 (2010).
23. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO?OVAR?22 trial. Lancet 361, 2099-2106 (2003).
24. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinumsensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24, 4699-4707 (2006).
25. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28, 3323-3329 (2010).
26. Richardson DL, Backes FJ, Seamon LG et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol. Oncol. 111, 461-466 (2008).
27. Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled Phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039-2045 (2012).
28. Baumann KH, du Bois A, Meier W et al. A Phase II trial (AGO 211) in platinumresistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann. Oncol. 23(9), 2265-2271 (2012).
29. Aigner J, Bischofs E, Hallscheidt P et al. Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment. Anticancer Drugs 22, 1030-1033 (2011).
30. Biagi JJ, Oza AM, Chalchal HI et al. A Phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann. Oncol. 22, 335-340 (2011).
31. Friedlander M, Hancock KC, Rischin D et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol. Oncol. 119, 32-37 (2010).
32. Welch SA, Hirte HW, Elit L et al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int. J. Gynecol. Cancer 20, 787-793 (2010).
33. Ferrara N, Hillan KJ, Gerber HP et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004).
34. Karlan BY, Oza AM, Richardson GE et al. Randomized, double-blind, placebocontrolled Phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J. Clin. Oncol. 30, 362-371 (2012).
35. Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA?301 Phase III randomized trial. Ann. Oncol. 22, 39-48 (2011).
36. Kaye SB, Colombo N, Monk BJ et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann. Oncol. 22, 49-58 (2011).
37. Sehouli J, Alfaro V, Gonzalez-Martin A. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. Ann. Oncol. 23, 556-562 (2012).
38. Ledermann JA. Benefits of enhancing the platinum-free interval in the treatment of relapsed ovarian cancer: more than just a hypothesis? Int. J. Gynecol. Cancer 21(Suppl. 1), S9-S11 (2011).
39. Gladieff L, Ferrero A, De Rauglaudre G et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO Phase III trial. Ann. Oncol. 23(5), 1185-1189 (2012).
40. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71, 1397-1412 (2011).
41. Sehouli J, Stengel D, Harter P et al. Topotecan weekly versus conventional 5 day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter Phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J. Clin. Oncol. 29, 242-248 (2011).
42. Lortholary A, Largillier R, Weber B et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized Phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann. Oncol. 23, 346-352 (2012).
43. Nishimura S, Tsuda H, Hashiguchi Y et al. Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis. Int. J. Gynecol. Cancer 17, 159-163 (2007).
44. Coleman RL, Brady WE, McMeekin DS et al. A Phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinumresistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 122, 111-115 (2011).
45. Rustin G, Reed N, Jayson GC et al. A Phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann. Oncol. 22, 2411-2416 (2011).
46. Dizon DS, Blessing JA, Penson RT et al. A Phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 125(2), 367-371 (2012).
47. Coleman RL, Duska LR, Ramirez PT et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 12, 1109-1117 (2011).
48. Ramasubbaiah R, Perkins SM, Schilder J et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a Phase I/II study of the Hoosier Oncology Group. Gynecol. Oncol. 123, 499-504 (2011).
49. Sanchez-Munoz A, Mendiola C, Perez-Ruiz E et al. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology 79, 98-104 (2010).
50. Naumann RW, Coleman RL, Burger RA et al. PRECEDENT: a randomized Phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinumresistant ovarian cancer. J. Clin. Oncol. 29(Suppl.), Abstract 5045 (2011).
51. Emons G, Tomov S, Harter P et al. Phase II study of AEZS?108 (AN?152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. J. Clin. Oncol. 28(15 Suppl.), Abstract 5035 (2010).
52. Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP?ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30, 372-379 (2012).
53. Pujade-Lauraine E, Hilpert F, Weber B et al. AURELIA: a randomized Phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J. Clin. Oncol. 30(15 Suppl.), Abstract LBA5002 (2012).
54. Vergote I, Joly F, Katsaros D et al. Randomized Phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a GCIG and EORTC-GCG study. J. Clin. Oncol. 30(Suppl.), Abstract LBA5000 (2012).
55. Bookman MA, Darcy KM, Clarke-Pearson D et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21, 283-290 (2003).
56. Hirte H, Oza A, Swenerton K et al. A Phase II study of erlotinib (OSI?774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol. Oncol. 118, 308-312 (2010).
57. Wagner U, du Bois A, Pfisterer J et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy-a Phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 26). Gynecol. Oncol. 105, 132-137 (2007).
58. Schilder RJ, Pathak HB, Lokshin AE et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol. Oncol. 113, 21-27 (2009).
59. Annunziata CM, Walker AJ, Minasian L et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin. Cancer Res. 16, 664-672 (2010).
60. Makhija S, Amler LC, Glenn D et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J. Clin. Oncol. 28, 1215-1223 (2010).
61. Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther. Adv. Med. Oncol. 3, 257-267 (2011).
62. Wysham WZ, Mhawech-Fauceglia P, Li H et al. BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS ONE 7(1), e30042 (2012).
63. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N. Engl. J. Med. 366(15), 1382-1392 (2012).
64. Penson RT, Whalen C, Lasonde B et al. A Phase II trial of iniparib (BSI?201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J. Clin. Oncol. 29(Suppl.), Abstract 5004 (2011).
65. Hasan J, Ton N, Mullamitha S et al. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br. J. Cancer 93, 647-651 (2005).
66. Zheng H, Kavanagh JJ, Hu W et al. Hormonal therapy in ovarian cancer. Int. J. Gynecol. Cancer 17, 325-338 (2007).
67. Konigsrainer I, Beckert S, Becker S et al. Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbecks Arch. Surg. 396, 1077-1081 (2011).
68. Spiliotis J, Vaxevanidou A, Sergouniotis F et al. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J. BUON 16, 74-79 (2011).
69. Roviello F, Pinto E, Corso G et al. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J. Surg. Oncol. 102, 663-670 (2010).
70. Ceelen WP, Van Nieuwenhove Y, Van Belle S et al. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann. Surg. Oncol. 19(7), 2352-2359 (2009).
71. Chua TC, Robertson G, Liauw W et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J. Cancer Res. Clin. Oncol. 135, 1637-1645 (2009).
72. Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 14, 683-694 (2009).
73. Vasey PA, Shulman LN, Campos S et al. Phase I trial of intraperitoneal injection of the E1B?55?kd-gene-deleted adenovirus ONYX?015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/ refractory epithelial ovarian cancer. J. Clin. Oncol. 20, 1562-1569 (2002).
74. Galanis E, Hartmann LC, Cliby WA et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 70, 875-882 (2010).
75. Stoeckel J, Hay JG. Drug evaluation: Reolysin-wild-type reovirus as a cancer therapeutic. Curr. Opin Mol. Ther. 8, 249-260 (2006).
76. Vermeij R, Leffers N, Hoogeboom BN et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm Phase II study. Int. J. Cancer 131(5), e670-e680 (2011).
77. Rahma OE, Ashtar E, Czystowska M et al. A gynecologic oncology group Phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol. Immunother. 61, 373-384 (2012).
78. Dobrzanski MJ, Rewers-Felkins KA, Quinlin IS et al. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin. Immunol. 133, 333-352 (2009).
79. Gao Y, Liu Z, Chen X et al. Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study. BMC Cancer 11, 439 (2011).
80. Barney BM, Petersen IA, Dowdy SC et al. Intraoperative electron beam radiotherapy (IOERT) in the management of recurrent ovarian malignancies. Int. J. Gynecol. Cancer 21, 1225-1231 (2011).
81. Lee SW, Park SM, Kim YM et al. Radiation therapy is a treatment to be considered for recurrent epithelial ovarian cancer after chemotherapy. Tumori 97, 590-595 (2011).
82. Kunos CA, Sill MW, Buekers TE et al. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a Phase I study of the Gynecologic Oncology Group. Gynecol. Oncol. 120, 224-228 (2011).
83. Oza A, Cibula D, Oaknin A et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label Phase II study. J. Clin. Oncol. 30(Suppl.), Abstract 5001 (2012).
84. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur. J. Cancer doi:10.1016/j.ejca.2012.04.001 (2012) (Epub ahead of print).